AbbVie ABBV continues to build momentum with its oncology franchise, with the recent FDA approval for Emrelis. This ...

Which cancer drug developers are attractive takeover targets? We asked Seeking Alpha analysts BioCGT Investor, ALLKA Research and Zach Hartman for their picks. BioCGT Investor: Cardiff Oncology ...

The companies Pathos AI, Taysha Gene Therapies, and Abeona Therapeutics bagged the biggest biotech funding rounds overall in ...

Accordingly, investing in AI-driven precision oncology companies presents a compelling long-term opportunity for investors. BioXcel: The company expedites the discovery and development of new ...

While oncology and immuno-oncology companies have always been at the top of acquisition targets, the lucrative obesity sector and gene-editing space are in spotlight as of now. The Zacks ...

Almost six years on, we're one of the fastest growing oncology companies in the world. We continue to drive forward with this approach supporting patients with cancer in the UK, and around the world.

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ...

Kura Oncology and Kyowa Kirin submitted data from the KOMET-001 trial, which the agency will review and decide whether to approve the drug by Nov. 30.

Introduction Oncology drugs are medications used to prevent or treat cancer. These include chemotherapy, targeted therapy, immunotherapy, and h ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.